This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Is Bavarian Nordic (BVNRY) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Bavarian Nordic (BVNRY) and Dare Bioscience, Inc. (DARE) have performed compared to their sector so far this year.
Is Bavarian Nordic (BVNRY) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should Value Investors Buy Bavarian Nordic (BVNRY) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Bavarian Nordic (BVNRY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Bavarian Nordic (BVNRY) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Are Investors Undervaluing Bavarian Nordic (BVNRY) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Bavarian Nordic (BVNRY) Surges 8.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
Bavarian Nordic (BVNRY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Here's Why Momentum in Bavarian Nordic (BVNRY) Should Keep going
by Zacks Equity Research
Bavarian Nordic (BVNRY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Here's Why Bavarian Nordic (BVNRY) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Bavarian Nordic (BVNRY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Bavarian Nordic (BVNRY) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
Bavarian Nordic (BVNRY) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Bavarian Nordic (BVNRY)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
Bavarian Nordic (BVNRY) Soars 7.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Bavarian Nordic (BVNRY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
All You Need to Know About BAVARIAN NORDIC (BVNRY) Rating Upgrade to Buy
by Zacks Equity Research
BAVARIAN NORDIC (BVNRY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is BAVARIAN NORDIC (BVNRY) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (BVNRY) Outperforming Other Medical Stocks This Year?
BAVARIAN NORDIC (BVNRY) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
BAVARIAN NORDIC (BVNRY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is BAVARIAN NORDIC (BVNRY) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (BVNRY) Outperforming Other Medical Stocks This Year?